U.S. Markets open in 1 hr 30 mins
  • S&P Futures

    +2.50 (+0.06%)
  • Dow Futures

    -16.00 (-0.05%)
  • Nasdaq Futures

    +40.25 (+0.27%)
  • Russell 2000 Futures

    +15.60 (+0.71%)
  • Crude Oil

    +0.30 (+0.42%)
  • Gold

    -4.00 (-0.22%)
  • Silver

    +0.16 (+0.65%)

    -0.0013 (-0.1063%)
  • 10-Yr Bond

    0.0000 (0.00%)
  • Vix

    +1.20 (+6.83%)

    +0.0002 (+0.0111%)

    +0.3090 (+0.2815%)

    +2,663.28 (+7.00%)
  • CMC Crypto 200

    +75.12 (+8.57%)
  • FTSE 100

    +15.28 (+0.22%)
  • Nikkei 225

    -388.56 (-1.39%)

Kristin Yarema Is The SVP & Chief Commercial Officer of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) And They Just Picked Up 165% More Shares

·3 min read

Those following along with Atara Biotherapeutics, Inc. (NASDAQ:ATRA) will no doubt be intrigued by the recent purchase of shares by Kristin Yarema, SVP & Chief Commercial Officer of the company, who spent a stonking US$500k on stock at an average price of US$14.57. That increased their holding by a full 165%, which arguably implies the sort of confidence required for a shy sweet-natured nerd to ask the most popular kid in the school to go out on a date.

View our latest analysis for Atara Biotherapeutics

The Last 12 Months Of Insider Transactions At Atara Biotherapeutics

In fact, the recent purchase by Kristin Yarema was the biggest purchase of Atara Biotherapeutics shares made by an insider individual in the last twelve months, according to our records. That implies that an insider found the current price of US$15.36 per share to be enticing. That means they have been optimistic about the company in the past, though they may have changed their mind. We do always like to see insider buying, but it is worth noting if those purchases were made at well below today's share price, as the discount to value may have narrowed with the rising price. The good news for Atara Biotherapeutics share holders is that an insider was buying at near the current price. Kristin Yarema was the only individual insider to buy during the last year.

You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!


There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Does Atara Biotherapeutics Boast High Insider Ownership?

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. We usually like to see fairly high levels of insider ownership. It appears that Atara Biotherapeutics insiders own 1.1% of the company, worth about US$14m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

So What Does This Data Suggest About Atara Biotherapeutics Insiders?

It's certainly positive to see the recent insider purchase. We also take confidence from the longer term picture of insider transactions. But we don't feel the same about the fact the company is making losses. Insiders likely see value in Atara Biotherapeutics shares, given these transactions (along with notable insider ownership of the company). In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Atara Biotherapeutics. Every company has risks, and we've spotted 3 warning signs for Atara Biotherapeutics you should know about.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.